Effectiveness of the Erbisol® class in complex treatment of patients with liver cirrhosis

Abstract

Liver cirrhosis (LC) frequently results in severe complications, high mortality rate and disability in patients suffering from this disease, thus necessitating the study of its course, diagnosis and management. The principle of gradual elimination of pathological syndromes is fundamental in the treatment of LC. Complex therapy requires the use of medicines that act on the general links of pathogenesis. As LC causes damage to the cellular structure of the liver as well as interferes with the normal functioning of other organs and systems, it requires the prescription of medicines with metabolic and immunomodulatory properties. Experimental and clinical results of trials of Erbisol injections necessitated the study of their therapeutic properties in patients with LC. Immunomodulation, hepatoprotection and hepatoreparation play a crucial role in the management of LC.